clinical trial · NCT04133636
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Janssen Research & Development, LLC·phase2·active not recruiting·n = 208
Multiple MyelomaJNJ-68284528LenalidomideDaratumumabBortezomibDexamethasone
brief summary
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
started
Nov 7, 2019
primary completion
Feb 26, 2027
completion
Aug 25, 2028
last updated
Jul 6, 2026
official title
68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol